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Local delivery of neurotrophic factors is a pillar of neural repair strategies in the peripheral nervous system.Themain disadvantage
of the free growth factors is their short half-life of few minutes. In order to prolong their activity, we have conjugated to iron
oxide nanoparticles three neurotrophic factors: nerve growth factor (𝛽NGF), glial cell-derived neurotrophic factor (GDNF), and
basic fibroblast growth factor (FGF-2). Comparative stability studies of free versus conjugated factors revealed that the conjugated
neurotrophic factors were significantly more stable in tissue cultures and in medium at 37∘C. The biological effects of free versus
conjugated neurotrophic factors were examined on organotypic dorsal root ganglion (DRG) cultures performed in NVR-Gel,
composed mainly of hyaluronic acid and laminin. Results revealed that the conjugated neurotrophic factors enhanced early nerve
fiber sprouting compared to the corresponding free factors. The most meaningful result was that conjugated-GDNF, accelerated
the onset and progression of myelin significantly earlier than the free GDNF and the other free and conjugated factors. This is
probably due to the beneficial and long-acting effect that the stabilized conjugated-GDNF had on neurons and Schwann cells.
These conclusive results make NVR-Gel enriched with conjugated-GDNF, a desirable scaffold for the reconstruction of severed
peripheral nerve.
1. Introduction
In case of peripheral nerve injuries with long distance
defects (gaps), autologous nerve grafting is the treatment
of choice. However, the availability of autologous nerve
grafts is limited especially when a large amount of grafting
material is needed, because it requires sacrifices of healthy
nerves [1]. Therefore, many efforts are being made to develop
artificial nerve grafts. The artificial nerve grafts are usually
composed of conduits, which guide the regenerating axons
to the distal nerve stump, filled with biomaterials deco-
rated with neurotrophic factors (neuronal growth factors)
[2].
Neurotrophic factors are signaling proteins which sup-
port neural survival and axonal growth. In addition, neu-
rotrophic factors play a significant role in the maintenance
of neuronal function throughout an entire lifetime.There are
a variety of neurotrophic factors that have been identified
and studied at various levels from molecular interactions
to macroscopic tissue responses (reviewed in [3–6]). In the
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present studywe focused on three neurotrophic factors: nerve
growth factor (𝛽NGF), glial cell-derived neurotrophic factor
(GDNF), and basic fibroblast growth factor (FGF-2).
NGF (discovered in the early 1950s by Rita Levi-
Montalciniwhowon the 1986Nobel Prize inMedicine for this
discovery [7]) is a polypeptide composed of three subunits
alpha, beta, and gamma. Only the beta subunit (𝛽NGF) is
responsible for the physiological activity ascribed to NGF,
and it is active in the absence of the other two subunits [8].
𝛽NGF is vital for the development and maintenance of both
central and peripheral nervous system neurons. It is known
to regulate the growth and differentiation of sympathetic
and sensory neurons. In addition, 𝛽NGF plays a key role in
nerve injury repair and in preventing neuronal degeneration
(reviewed in [3, 9]).
GDNF has been demonstrated to enhance the survival
and outgrowth of motor neurons as well as sensory neurons
[3]. It also promotes in vivo myelination of unmyelinated
nerve fibers [10, 11]. This factor was also found to act on
dopaminergic neurons in the substantia nigra, whose death
is responsible for Parkinson’s disease [12, 13].
FGF-2 is a potent mitogenic polypeptide which induces
cell divisions in a variety of mesodermal cell types and
cells of neuroectodermal origin (reviewed in [14, 15]). FGF-
2 has been shown to promote neuron survival, spinal cord
regeneration, peripheral nerve regeneration, and neuritoge-
nesis of motor neurons [16–19]. FGF-2 also stimulates the
proliferation and differentiation of neuronal precursor cells
from mouse and human olfactory epithelium [3, 14, 20–22]
as well as of Schwann cells [23].
Because of their positive effect on neurons, neurotrophic
factors are attractive candidates for therapy of acute injuries
to the nervous system (such as reconstruction of peripheral
nerve after a severe segment loss, especially in cases of a long
distance nerve defect) as well as chronic neurodegenerative
diseases (such as Alzheimer’s, Huntington’s, and Parkinson’s
disease) (reviewed in [3, 4]). Also, in laboratory research,
it is common to add neurotrophic factors to cell cultures
to enhance neuronal cell regeneration. However, the main
disadvantage of free growth factors is their short in vivo half-
life time due to rapid enzymatic degradation, which leads to
the loss of their biological activity after a short period of time
[24]. For example, the half-life time of FGF-2, brain derived
neurotrophic factor (BDNF), and 𝛽NGF in blood is 1.5–3,
10, and 30min, respectively [25–29]. In order to prolong
their activity and bioavailability, it has been suggested to
conjugate the growth factors onto or encapsulated within
nanostructures of diverse types of synthetic and natural
materials [24, 30].
In the present study, iron oxide nanoparticles were used
for neurotrophic factor conjugation. These nanoparticles
provide magnetic properties, high surface-area-to-volume
ratio, biocompatibility, and biodegradability. Iron oxidemag-
netic nanoparticles are considered to be nontoxic and are
already being used for various biomedical applications, such
as diagnostics, cell labeling and sorting, DNA separation,
MRI and X-ray contrast agents, gene and drug delivery, and
hyperthermia (reviewed in [21, 22]).Themagnetic properties
of these nanoparticlesmay also be used for targeting of a drug
immobilized on magnetic materials under the action of an
external magnetic field [31]. In addition, the magnetic prop-
erties of the iron oxide nanoparticles enable their purification
from excess reagents, during the synthesis process, easily by
using magnetic columns.
The aim of the present study was to examine in vitro
the stability and the biological effects of 𝛽NGF, GDNF, and
FGF-2 conjugated covalently to iron oxide nanoparticles,
with the prospective to use them in artificial conduits for
peripheral nerve reconstruction. Our studies were conducted
on cultures of organotypic dorsal root ganglion (DRG) seeded
in NVR-Gel [32] as a possible hydrogel scaffold for filling
artificial conduit [2].
2. Materials and Methods
2.1. Synthesis of Iron Oxide Nanoparticles. Magnetic iron
oxide nanoparticles were prepared in two main ways as
follows.
(a) Gelatin coated iron oxide nanoparticles contain-
ing the fluorescent probe rhodamine of 15.0 ±
1.4 nm dry diameter were prepared by nucleation
and then controlled the growth of iron oxide layers
onto rhodamine isothiocyanate (RITC) conjugated
gelatin/iron oxide nuclei, according to our previous
publications [21, 33].
(b) Dextran coated iron oxide magnetic nanoparticles of
9.5 ± 0.9 nm dry diameter were prepared as described
previously by Molday and Mackenzie [34].
2.2. Conjugation of Neural Growth Factors to the Iron Oxide
Nanoparticles. Covalent conjugation of 𝛽NGF, GDNF, or
FGF-2 (PeproTechAsia, Israel) to the surface of the iron
oxide nanoparticles (each type individually) was performed
as described previously [21, 22, 33]. Briefly, the iron oxide
nanoparticles coated either with gelatin (which provides
hydroxyl and primary amine functional groups) or with dex-
tran (which provides hydroxyl groups) were functionalized
with activated double bonds by interacting the functional
groups of the gelatin or dextran with excess divinyl sulfone
(DVS) via the Michael addition reaction. The residual acti-
vated double bonds were then used for covalent binding
of the different neurotrophic factors, again via the Michael
addition reaction. The concentration of each neurotrophic
factor conjugated to the nanoparticles was determined by
using the appropriate ELISA Kit (PeproTech Asia, Israel, and
Boster Immunoleader, USA).
2.3. Comparative Stability Studies of Free versus Conjugated
Neurotrophic Factors
(a) Stability in Cell Cultures. Free or conjugated neu-
rotrophic factors were added once to the medium
of dissociated DRG cultures (final concentration
10 ng/mL, each factor). The cultures were placed in
a 5% CO
2
incubator at 37∘C for 9 days. The culture
medium was not changed during the entire period of
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the experiment, and aliquots from it were collected
at different points in time after cultivation. The
concentrations of the residual factors in the aliquots
were measured using the appropriate ELISA Kit.
(b) Stability at 37∘C inMedium. Samples of culturemedia
containing free or conjugated neurotrophic factors
(final concentration 10 ng/mL, each factor) were kept
at 37∘C. Aliquots were collected at different time
points, and the concentration of the residual free and
conjugated neurotrophic factors in the samples was
measured as described above.
2.4. Culture Medium. The culture medium was prepared
from 90% Dulbecco’s modified eagle medium-nutrient mix-
ture F-12 (DMEM-F12), 10% heat-denatured fetal calf serum
(FCS), 6 g/L D-glucose, 2 nM glutamine, 25 𝜇g/mL gen-
tamycin, and 50 ng/mL IGF-I (all purchased from Biological
Industries, Israel).
2.5. NVR-Gel for Neuronal Cultivation. NVR-Gel (NVR Labs
proprietary [32]) is composed of twomain components: high
molecular hyaluronic acid (HA, 3× 106Da) and laminin, both
known to be inherent elements of the extracellular matrix.
For cell cultivation, HA of 1% (BTG Polymers, Israel) was
diluted with culture medium to the concentrations of 0.3–
0.5%. Laminin (Sigma) was then mixed with the diluted
HA to a final concentration of 10 ng/mL. Free or conjugated
neurotrophic factors (𝛽NGF, GDNF, and FGF-2) were finally
added, separately or together (10 ng/mL of each factor), to
complete the NVR-Gel composition.
2.6. Preparation of Organotypic DRG Cultures. All the exper-
iments were carried out and authorized by the local ethics
committee recognized by the Israeli authorities for animal
experimentation. Stationary organotypic DRG cultures were
prepared from rat fetuses (gestational day 15, Lewis inbred,
Harlan, Israel). Immediately after dissection, the isolated gan-
glia were cut with a McIlwain tissue chopper into small slices
(of 400 𝜇m thickness) which were then seeded in 12 well-
culture plates (either directly on the plastic or on glass cover
slips) containing 0.75mLofNVR-Gel (one explant eachwell).
Cultures received free or conjugated neurotrophic factors
(10 ng/mL final concentration, each factor separately) once in
the gel at seeding and subsequently with the nutrientmedium
at each consecutive feeding. Monitoring of the DRG growth
pattern (neuronal sprouting, establishment of cultures, and
myelin formation) was done by daily phase contrast micro-
scopic observations from 24 hours after setting the cultures
onward.
Experiments aimed at examining the effect of neu-
rotrophic factors on early neuronal sprouting; cultures were
performedwith 12 repetitions (12wells) for each neurotrophic
factor. During the first week in culture, ganglia which exhib-
ited nerve outgrowth were counted.
Experiments aimed at examining the effect of neu-
rotrophic factors on early onset and progressionof myelin
were performed in triplicate for each neurotrophic factor.
Cultures with myelinated fibers, which in phase contrast
microscopyappear confined by two dark lines along both
sides of the fiber (due to the optical property of the myelin
sheaths lipids), were recorded and photographed. The myeli-
nated cultures were fixed for histological and immunocy-
tochemical staining as well as for Transmission Electron
Microscopy (TEM).
2.7. Immunofluorescence of Myelinated DRG Cultures. After
removal of the culture medium, the DRG cultures were
washed with phosphate buffered salt solution (PBS) and fixed
in 4% paraformaldehyde for 15min and then washed again
with PBS. The fixed cells were permeabilized with 0.1% of
Triton X-100 in PBS and then immunoblocked (to avoid
nonspecific staining) with a 1% bovine serum albumin (BSA)
in PBS for 1 h at room temperature. The specimens were then
double incubated with mouse antimyelin basic protein anti-
bodies (MBP, Covance, Nr. SMI 94 R, 1: 250) to visualize the
myelin and rabbit antineurofilament antibodies (NF, Novus
Biologicals, 1: 500) to visualize the neurite outgrowth.Thepri-
mary antibodies were diluted in 0.1% BSA and 0.05% Tween-
20 in PBS (diluents buffer) and incubated with the specimens
overnight at 4∘C. After rinsing with 0.05% Tween-20 in PBS
(wash buffer), the DRG specimens were incubated for 1 h at
room temperature with the appropriate secondary antibod-
ies: Alexa-Fluor-488-conjugated donkey anti-mouse IgG or
Alexa-Fluor-594-conjugated donkey anti-rabbit IgG (Jackson
ImmunoResearch, USA, 1: 800 in a diluent buffer). Finally,
the samples were rinsed again with wash buffer and mounted
with mounting medium (Immco Diagnostics, USA). Myeli-
nated cultures were alternatively stained with Luxol Fast
Blue. All of the images were observed with an Olympus IX70
microscope.
2.8. Transmission Electron Microscopy (TEM) Analysis.
Organotypic DRG cultures, detached from the glass or
the plastic substrates, were fixed in 2.5% glutaraldehyde,
washed in Sorensen phosphate buffer 0.1M (pH 7.4) with
1.5% sucrose, and then fixed in 2% osmium tetroxide for
2 h. After dehydration in ethanol, samples were cleared in
propylene oxide and embedded in Glauerts’ embedding
mixture of resins consisting of equal parts of Araldite M
and Araldite Harter, HY 964 (Merck, Darmstadt, Germany),
containing 0.5% of the plasticizer dibutyl phthalate and
1-2% of the accelerator 964, DY 064 (Merck, Darmstadt,
Germany). Transverse cross sections of 70 nm were obtained
using an Ultracut UCT ultramicrotome (Leica, Wetzlar,
Germany). Sections were then stained with uranyl acetate
and lead citrate and examined by a JEM-1010 transmission
electron microscope (JEOL, Tokyo, Japan) equipped with
a Mega-View-III digital camera and a Soft-Imaging-System
(SIS, Mu¨nster, Germany) for the computerized acquisition
of the images.
2.9. Statistical Analysis. Statistical analysis was performed by
Student’s t-test. The results are expressed as mean ± standard
deviation (SD).𝑃 < 0.05was accepted as indicating statistical
significance.
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Figure 1: Stability of free versus conjugated neurotrophic factors at 37∘C in the absence ((a1), (b1), and (c1)) and in the presence ((a2), (b2),
and (c2)) of cells. In the upper row free or conjugated neurotrophic factors (GDNF, 𝛽NGF, and FGF-2) were added to culture medium,
each type separately (10 ng/mL, final concentration), and placed at 37∘C (in the absence of cells). Aliquots were collected after different time
points, and the concentration of the residual factor in the samples was measured using an appropriate ELISA kit. In the lower row, the
same concentrations of free or conjugated neurotrophic factors were added once to dissociate dorsal root ganglia (DRG) cell cultures at the
beginning of the experiment. The culture medium was not changed during the experiment and aliquots from it were collected at different
days after cultivation. The concentration of the residual factors in the aliquots was measured as described above. The data are presented as
mean ± SD in triplicate (∗𝑃 < 0.01, ∗ ∗ 𝑃 < 0.001).
3. Results
3.1. Long-Term Stability of Free versus Conjugated Neu-
rotrophic Factors. The stability of the free and conjugated
neurotrophic factors (GDNF, 𝛽NGF, and FGF-2) against
various enzymes and inhibitors, existing in serum or secreted
from cells, was examined in tissue cultures and in medium
alone at 37∘C.
Results shown in Figure 1 demonstrate that the concen-
tration of the neurotrophic factor decreased gradually over
time; however, the conjugated neurotrophic factors were
significantlymore stable than the free factors in bothmedium
alone ((a1)–(c1)) and tissue cultures ((a2)–(c2)). Among the
conjugated factors, themost stablewas the conjugated-GDNF
((a1) & (a2)), followed by the conjugated-FGF-2 with a
moderate stability ((c1) & (c2)), and the least stable was
the conjugated-𝛽NGF ((b1) & (b2)). During the 9 days of
the experiment, the concentration of the conjugated-GDNF
remained almost stable at around 100%, while the concentra-
tion of free GDNF was gradually decreased to 57.3 ± 7.0% in
medium and 31.2 ± 2.1% in culture. Regarding the stability
of FGF-2, after about a week, the residual concentrations
of the conjugated-FGF-2 in medium and in tissue culture
were reduced to 70.1 ± 5.7% and 38.6 ± 1.4%, respectively.
On the other hand, the residual concentrations of the free
FGF-2 were significantly lower than that of the conjugated
factor: 38.2 ± 1.6% and 18.7 ± 3.2%, in medium and in the
tissue culture, respectively. As to the 𝛽NGF, after 6 days,
the residual concentrations of the conjugated-𝛽NGF were
reduced to 32.6±2.0% inmedium and 14.6±1.0% in culture.
BioMed Research International 5
0
10
20
30
40
50
60
70
80
90
100
3 4 8
Ex
pl
an
ts 
w
ith
 sp
ro
ut
in
g 
(%
)
Days in culture
Control
Free GDNF
Conjugated-GDNF
∗∗
∗
∗
∗
Figure 2: Enhancement of early nerve fibre outgrowth by
conjugated-GDNF.The graph shows the percentage of explants (out
of 12) which exhibited nerve fiber sprouting in the absence and
the presence of free versus conjugated-GDNF as a function of time
(days) in culture. The data are presented as mean ± SD from 3
repeated experiments. ∗ Significant difference (𝑃 < 0.05) compared
to the corresponding free group.∗∗ Significant difference (𝑃 < 0.05)
compared to the corresponding control group.
However, the free 𝛽NGF was decreased more significantly to
14.6 ± 1.0% in medium and 2.8 ± 1.5% in tissue culture.
3.2. Effects of Free versus Conjugated Neurotrophic Fac-
tors on DRG Organotypic Cultures. The overall effect of
the exposure of DRG explants to each of the three con-
jugated neurotrophic factors is represented by the early
phenomenon of sprouting compared to cultures that were
exposed to free factors and control. During the first days
of cultivation, the number of DRG explants that exhibited
an early sprouting, following the exposure to conjugated-
GDNF, was increased significantly by 30% compared to free
GDNF and by 40% compared to controls (without neu-
rotrophic factors) (Figure 2). The most intensive sprouting
was observed in cultures which were exposed to 𝛽NGF
and GDNF (Figure 3). During the establishment of the
cultures (after the first week of cultivation), the regenerated
nerve fibers became longer, thicker, and ramified, until the
formation of neuronal networks, mainly in cultures exposed
to conjugated-GDNF and 𝛽NGF (Figure 4). However, only
conjugated-GDNF accelerated significantly the onset of
myelin.
The effect of free versus conjugated neurotrophic factors
on the onset of myelin in organotypic DRG cultures is shown
in Figure 5. The results demonstrate that the onset of myelin
(the appearance of initial segments of myelinated axons) was
observed first in cultures exposed to conjugated-GDNF. In
these cultures, onset of myelin was already observed after
14 ± 2.2 days of cultivation. Furthermore, during subsequent
days,most of the fibers in cultures incubatedwith conjugated-
GDNF became heavily myelinated (Figure 6). In contrast,
the onset of myelin in cultures exposed to free GDNF
was observed significantly later, that is, after 20.8 ± 4.3
days of cultivation (𝑃 = 0.0006, compared to conjugated-
GDNF). The onset of myelin in cultures exposed to free
and conjugated-𝛽NGF was observed only after more than
3 weeks of cultivation (on days 27.3 ± 2.9 and 23.8 ±
4.0, resp.). Although in these cultures the onset of myelin
was advanced (𝑃 < 0.05) in comparison to control cul-
tures (without neurotrophic factors), yet it was significantly
decelerated (𝑃 < 0.001) compared to cultures exposed to
conjugated-GDNF. The onset of myelin in cultures exposed
to free and conjugated-FGF-2 was observed around the
fourth week in culture, on days 29.3 ± 3.2 and 27.3 ±
6.0, respectively, which demonstrates a nonsignificant (𝑃 >
0.05) acceleration compared to controls, in which the phe-
nomenon occurred 34.0 ± 4.2 days after cultivation. Results
similar to those obtained from control cultures were also
obtained in cultures which were exposed to naked iron oxide
nanoparticles.
3.3. TEM Analysis. TEM analysis was made on early myeli-
nated DRG organotypic cultures (14 days after seeding)
performed in NVR-Gel enriched with conjugated-GDNF.
TEM observations (Figure 7) confirmed the light micro-
scopic observations regarding the existence of myelin around
the nerve fibers. However, TEM analysis allowed further
observation of the very small single iron oxide nanoparticles
and to determine their localization. In Figure 7, a transverse
section ((a) and (b)) and a longitudinal section ((c) and
(d)) of a nerve fiber with its myelin sheaths are shown. The
ultrastructural analysis allowed us to observe single/distinct
iron oxide nanoparticles (of average size of around 10–15 nm)
localized between the ensheathing myelin lamellae (black
arrows) and within the axon (white arrows). These TEM
observations clearly demonstrate that the GDNF-conjugated
iron oxide nanoparticles were internalized by neurons and by
Schwann cells.
4. Discussion
The present study describes a novel strategy for DRG culti-
vation in NVR-Gel containing neurotrophic factors (𝛽NGF,
GDNF, and FGF-2) covalently conjugated to iron oxide
nanoparticles.Theneurotrophic factors were stabilized by the
covalent conjugation to the iron oxide nanoparticles. This
was demonstrated by comparative stability studies (Figure 1)
in which the conjugated neurotrophic factors were signifi-
cantly more stable than the free factors in cell cultures and
medium at 37∘C. The increased stability of the conjugated
neurotrophic factors is probably due to the fact that the
coupling of proteins to nanoparticles protects them from
proteolytic enzymes and inhibitors existing in the serum or
secreted by the cells and thus prolongs their half-life time
and enhances their activity in vitro and in vivo, as described
previously [21, 22, 33, 35–39].
The biological activity of the neurotrophic factors was
examined in cultures prepared in NVR-Gel. The results
showed that the gel adhered easily the DRG slices to the
glass or plastic substrates and subsequently supported cell
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Figure 3: Early sprouting of thin and long nerve fibers from DRG explants 24 h after cultivation in NVR-Gel enriched with growth factors
conjugated to iron oxide nanoparticles as follows: (a) Conjugated-𝛽NGF, (b) Conjugated-GDNF, (c) Conjugated-FGF-2, (d) Control (without
growth factors) (phase-contrast microscopy).
maturation and nerve fiber outgrowth in a three-dimensional
pattern. Similar properties of the gel have been demonstrated
previously, both in neuronal cell cultures [21, 40] and in
in vivo models of peripheral nerve injuries and spinal cord
injuries [41, 42].
Comparative studies on the biological effect of free versus
conjugated-𝛽NGF, -GDNF, and -FGF-2 on DRG cultures
revealed that during the first days of cultivation the con-
jugated neurotrophic factors had more beneficial effects
than the corresponding free neurotrophic factors on the
enhancement of early nerve fiber regeneration (Figure 2).
In the long-term cultures, the conjugated-GDNF had the
most significant efficacy (Figure 5), which was expressed
in acceleration of the myelin onset and subsequently the
progression of myelination. This is probably due to covalent
binding of the GDNF to the iron oxide nanoparticles, which
increases the conjugated neurotrophic factor stability and
prolongs its biological activity. As far as we know, there are
no other publications who report that GDNF conjugated to
nanoparticles, of any kind, enhances onset and progression
of myelin. Free GDNF had a significantly reduced effect in
comparison to the conjugated-GDNF.
The difference in the effect of conjugated-GDNF and
conjugated-𝛽NGF on the acceleration of myelin formation
in DRG cultures is intriguing since both conjugated factors
had a similar beneficial effect on early neurite outgrowth
and formation of axonal networks. Since myelin of the
peripheral nervous system is known to be formed only
around axons that have a diameter of 2 𝜇m and more,
we expected that myelin will equivalently form around
the thick axons in cultures incubated with either of neu-
rotrophic factors. However, the conjugated-GDNF accel-
erated the early onset and progression of myelin signifi-
cantly over the conjugated-𝛽NGF (𝑃 < 0.0001) (Figure 5).
This strongly indicates that conjugated-GDNF, but not the
𝛽NGF, has an additional beneficial effect on Schwann cells,
which results in the enhancement of the peripheral myelin
formation.
Indeed, the TEM images (Figure 7) clearly demonstrate
that a large number of iron oxide nanoparticles conjugated to
GDNF were internalized by neurons as well as by Schwann
cells. These results strongly support the hypothesis that
GDNF activates both on DRG neurons and Schwann cells.
This hypothesis is strengthened by Zhang et al. [11] who
reported that free GDNF, beside its effect on enhance-
ment of axonal regeneration in vivo and in vitro, signifi-
cantly increases the number of myelin sheaths produced by
Schwann cells. Similarly, Ho¨ke et al. [10] found that admin-
istration of free GDNF to adult rats alters axon-Schwann cell
units and promotesmyelination of unmyelinated nerve fibers.
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Figure 4: Establishment of cultures: neuronal networks composed of long, thick, and ramified neurites which are originating from DRG
explants cultures, 10 days after set-up in NVR-Gel enriched with neurotrophic factors conjugated to iron oxide nanoparticles as follows: (a)
Conjugated-𝛽NGF, (b) Conjugated-GDNF, (c) Conjugated-FGF-2 (phase-contrast microscopy).
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Figure 5: Effect of neurotrophic factors conjugated to iron oxide
nanoparticles versus free factors on the onset of myelin in DRG
organotypic cultures. The graph shows time elapsed (days) until
the appearance of the first segments of myelinated axons. Control
cultures have not been exposed to neurotrophic factors. The data
represented showsmean± SD from 15 repeated experiments. In each
experiment cultures were performed in triplicate for each type of
neurotrophic factor (∗𝑃 < 0.05, ∗ ∗ 𝑃 < 0.01, ∗ ∗ ∗𝑃 < 0.001).
5. Conclusion
These studies demonstrate that the covalent conjugation of
neurotrophic factors to iron oxide nanoparticles increases
their stability, preserves their activity, and even improves it.
Comparative biological studies performed on DRG cultures
in NVR-Gel revealed that the gel enriched with conjugated-
𝛽NGF, -GDNF, and -FGF-2 induced early nerve fiber regen-
eration significantly before the corresponding free neu-
rotrophic factors. Among the three conjugated neurotrophic
factors, the conjugated-GDNF had the most meaningful
effect on the early onset and the progression of myelin in
DRG cultures. The onset of myelin in cultures enriched
with conjugated-GDNF was detected 7 days earlier than in
cultures incubated with free GDNF and 21 days earlier than
in control cultures.
Our culture strategy, which combines the employment
of NVR-Gel and stabilized conjugated-GDNF, reveals that
the biomaterials evaluated could become a scaffold mate-
rial for a bioartificial nerve graft for long gap peripheral
nerve reconstruction. Such an implant will most likely
enhance regeneration and myelin formation of the dam-
aged axons and thus has potential to shorten the recovery
period. The organotypic DRG cultures in NVR-Gel enriched
with conjugated factors can also serve as an in vitro phar-
macological model for the research of demyelination and
8 BioMed Research International
100 𝜇m
(a)
100 𝜇m
(b)
100 𝜇m
(c)
100 𝜇m
(d)
200 𝜇m
(e)
100 𝜇m
(f)
Figure 6: Myelinated organotypic DRG cultures exposed to conjugated-GDNF (left column) versus nonmyelinated cultures (right column).
(a) and (b): Representative immunofluorescence images of a myelinated (day 12) versus nonmyelinated cultures, respectively. Neurites appear
in red (antineurofilament staining) and myelin sheaths appear in green (antimyelin basic protein staining). (c) and (d): Phase-contrast
microscope images of a heavily myelinated (day 16) versus nonmyelinated culture, respectively. Note the arrows in (c) which point to a
single birefringent myelinated nerve fibre (appears as a bright fibre confined by two dark lines along both its sides due to the optical property
of the myelin sheaths lipids). The arrows in (d) point to nonmyelinated fibres. (e): Staining of myelinated nerve fibres with Luxol Fast Blue.
(f): Phase-contrast microscope image (through a green filter) of individual DRG cells in a nonmyelinated culture.
remyelination in autoimmune diseases and in bacterial and
viral intoxications.
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Figure 7: TEM analysis of the localisation of GDNF-conjugated iron oxide nanoparticles: Myelinated organotypic DRG cultures 14 days after
seeding in NVR-Gel containing GDNF-conjugated nanoparticles were analysed. (a) and (b): Axon in transverse section. (c) and (d): Axon in
longitudinal section. The black arrows point to iron oxide nanoparticles between myelin lamellae and the white arrows point to iron oxide
nanoparticles in the axon.
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